Arama Sonuçları - Stål, Olle

Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and b... Yazar: Hilborn, Erik, Stål, Olle, Jansson, Agneta

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breas... Yazar: Hilborn, Erik, Stål, Olle, Alexeyenko, Andrey, Jansson, Agneta

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Low ERK Phosphorylation in Cancer-Associated Fibroblasts Is Associated with Tamoxifen Resistance in Pre-Menopausal Breast Cancer Yazar: Busch, Susann, Rydén, Lisa, Stål, Olle, Jirström, Karin, Landberg, Göran

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Yazar: Wegman, Pia, Elingarami, Sauli, Carstensen, John, Stål, Olle, Nordenskjöld, Bo, Wingren, Sten

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients Yazar: Hilborn, Erik, Sivik, Tove, Fornander, Tommy, Stål, Olle, Nordenskjöld, Bo, Jansson, Agneta

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer Yazar: Nordenskjöld, Anna, Fohlin, Helena, Fornander, Tommy, Löfdahl, Britta, Skoog, Lambert, Stål, Olle

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer Yazar: Karlsson, Elin, Veenstra, Cynthia, Gårsjö, Jon, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer Yazar: Jerevall, Piiha-Lotta, Jansson, Agneta, Fornander, Tommy, Skoog, Lambert, Nordenskjöld, Bo, Stål, Olle

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer Yazar: Sivik, Tove, Gunnarsson, Cecilia, Fornander, Tommy, Nordenskjöld, Bo, Skoog, Lambert, Stål, Olle, Jansson, Agneta

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer Yazar: Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer Yazar: Fohlin, Helena, Bekkhus, Tove, Sandström, Josefine, Fornander, Tommy, Nordenskjöld, Bo, Carstensen, John, Stål, Olle

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Yazar: Wegman, Pia, Vainikka, Linda, Stål, Olle, Nordenskjöld, Bo, Skoog, Lambert, Rutqvist, Lars-Erik, Wingren, Sten

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Exploring cancer register data to find risk factors for recurrence of breast cancer – application of Canonical Correlation Analysis Yazar: Razavi, Amir R, Gill, Hans, Stål, Olle, Sundquist, Marie, Thorstenson, Sten, Åhlfeldt, Hans, Shahsavar, Nosrat

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer Yazar: Lundgren, Katja, Tobin, Nicholas P., Lehn, Sophie, Stål, Olle, Rydén, Lisa, Jirström, Karin, Landberg, Göran

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Akt kinases in breast cancer and the results of adjuvant therapy Yazar: Stål, Olle, Pérez-Tenorio, Gizeh, Åkerberg, Linda, Olsson, Birgit, Nordenskjöld, Bo, Skoog, Lambert, Rutqvist, Lars Erik

Tam Metin Erişim Tam Metin Erişim

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response Yazar: Lehn, Sophie, Tobin, Nicholas P, Sims, Andrew H, Stål, Olle, Jirström, Karin, Axelson, Håkan, Landberg, Göran

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer Yazar: Schroeder, Brock, Zhang, Yi, Stål, Olle, Fornander, Tommy, Brufsky, Adam, Sgroi, Dennis C., Schnabel, Catherine A.

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer Yazar: Bostner, Josefine, Alayev, Anya, Berman, Adi Y., Fornander, Tommy, Nordenskjöld, Bo, Holz, Marina K., Stål, Olle

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype Yazar: Veenstra, Cynthia, Karlsson, Elin, Mirwani, Sanam Mirwani, Nordenskjöld, Bo, Fornander, Tommy, Pérez-Tenorio, Gizeh, Stål, Olle

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit Yazar: Bostner, Josefine, Karlsson, Elin, Pandiyan, Muneeswaran J., Westman, Hanna, Skoog, Lambert, Fornander, Tommy, Nordenskjöld, Bo, Stål, Olle

Tam Metin Erişim Tam Metin Erişim Tam Metin Erişim